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Sommario
L'obiettivo di questa tesi è quello di migliorare l'attuale formulazione
del primo modello nora sviluppato di cardiomiociti derivati da hiPSC, il
Paci2013, attraverso l'utilizzo: i) di un set di dati sperimentali di transienti
di Ca2+ e ii) di una procedura automatica per l'ottimizzazione dei parametri
del modello.
Il lavoro svolto per questa tesi si articola in diverse fasi. Dapprima è stata
introdotta nel modello una nuova formulazione del rilascio di Ca2+ dal reti-
colo sarcoplasmatico che riproduce in maniera più realistica un importante
fenomeno alla base della contrazione muscolare cardiaca. Successivamente
è stata eettuata una discriminazione dei dati sperimentali dei transienti di
Ca2+ tramite una procedura di classicazione non supervisionata al ne di
rendere il set di misure sperimentali più consitente con il modello in esame.
In seguito è stato implementato un framework di ottimizzazione parametrica
che, tramite la minimizzazione di una funzione costo, ha consentito di cali-
brare il modello sulla base dei dati sperimentali. Inne, in fase di validazione
del modello, sono state eettuate delle simulazioni di bloccanti di corrente
per valutare che gli eetti di tali bloccanti sul potenziale d'azione fossero
consistenti con dati sperimentali da letteratura .
In conlusione, questo lavoro di tesi tesi ha fornito in primis una nuova
versione del modello Paci2013 calibrata su dati sperimentali di transienti di
Ca2+ ed inoltre il framework di ottimizzazione parametrica, che rappresenta
uno strumento utile per lo sviluppo di modelli computazionali.
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Acronyms
AP Action Potential
APA Action potential amplitude
APD Action potential duration
APDxx Action potential duration at xx% of repolarization
MDP Maximum diastolic potential
TP Time to peak
RT1090 rise time that occurs to rise from the 10% to the 90% of Ca2+
transient amplitude
DT9010 decay time that occurs to decay from the 90% to the 10% of
Ca2+ transient amplitude;
RS1090 average rise slope from 10% to the 90% of Ca2+ transient
amplitude
DS9010 average decay slope from 90% to the 10% of transient
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CM Cardiomyocite
EC Excitation/contraction
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hESC-CM human embryonic stem cell-derived Cardiomyocyte
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+ current
If funny current
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+ /K+ pump
INaCa Na
+ /Ca2+
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CHAPTER I
Introduction: general overview about stem cell
technology and the cardiac modelling
In this chapter, an introduction about the stem cell is presented in order
to give the basic information about the wide world of the stem cell technol-
ogy. Later on, another introduction about the cardiac modelling is exposed,
in particular the Hodgkin-Huxley modelling paradigm. The aim is to pro-
vide the essential information to understand the work presented in the next
chapters
I.1 The stem cells
Stem cells are non-specialized cells, present in all the pluricellular organ-
ism and capable to transform into other dierent specialized cells though a
biological process called cellular dierentiation.
We can give this formal denition: a stem cell is a cell that can contin-
uously produce unaltered daughters and has the ability to produce daughter
cells that have dierent, more restricted properties"[1]. Thus, two funda-
mental properties can be dened:
• self-renewal: the ability to generate, through several division cycles, at
least one daughter equivalent to the mother cell with latent capacity of
1
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dierentiation[1].
• potency: the capacity to become, under some physiologic or experimen-
tal conditions, tissue or organ specic cell with certain properties[1].
So, dierent levels of stem cell potency, can be dened[2]:
• Totipotent: derive from the fusion of an egg cell and a sperm cell. They
are able to form the entire organism since they can dierentiate into
embryonic and extra-embryonic cell type, i. e. all the lineages needed
to build the whole organism;
• Pluripotent: they are able to dierentiate only into the embryonic cell
types, so they can form all the body cell lineage;
• Multipotent: can dierentiate into the cell types of a organic tissue;
• Oligopotent: able to dierentiate into two or more lineages within a
tissue;
• Unipotent: can develop into only a single cell lineage;
Stem cells can be distinguished in adult and embryonic. Adult stem cells are
present in some of our organs and tissues, such as spinal cord, and their task is
to regenerate the tissue or organ itself; they can be pluri, multi or unipotent.
Embryonic stem cells are derived from an embyro that develops after an
in-vitro fertilization of an egg cell (FigureI.1). In 1998 Thomson et al. [3]
were the rst ones to succeed in this procedure. After the fertilization of the
human oocyte and through a process called cleveage, a rapid division of the
zygote, a cluster of totipotent cells is produced. Then, passing through the
morula state, it reaches the blastocyst stage, in which two primary elements
are present:
• Trophloblast;
• Inner-cell mass;
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Then, slightly more than 2 weeks after the fertilization, a process called
gastrulation occurs on the inner cell mass. Through this process the 3 germ
layers are generated, each of them capable to dierentiate into a limited
number of phenotypes:
• Endoderm, the internal layer, that dierentiates into tissues such as
hepatic, pulmonary, vesical etc;
• Mesoderm,the intermediate layer, that dierentiates into bone, muscu-
lar, cardiac tissues, etc;
• Endoderm,the external layer, that dierentiates into dermal, nervous
tissues, etc;
The human embryonic stem cells (hESCs) are obtained by isolating the cells
from the inner cell mass of blastocyst and they can dierentiate into the tis-
sues produced by the three germ layers (FigureI.1). Thanks to their pluripo-
tency, hESCs could be the starting point to develop a novel therapeutic
approach for many diseases, such as cancer, but, on the other hand, they
could also raise some controversy concerning their proper ethical use.
I.2 Human induced pluripotent stem cell
Human induced pluripotent stem cells (hiPSCs) are pluripotent cells obtained
by reprogramming the DNA of human somatic cells. They have the same
properties of hESCs, such as self-renewal and potency, but they bring some
new advantages:
• There are no ethical issues, since no human embryos are used;
• It is possible to create a stem cell culture for a specic patient because
hiPSCs are obtained safely from a patient (for example from a skin
biopsy). This reduces the risk of rejection in case of transplant;
The rst experimental trials to produce hiPSCs were performed [4][5] intro-
ducing in the human adult dermal broblast 4 dierent reprogramming genes
through lentiviral vectors. These are: Oct-3/4, Sox2, Klf4, c-Myc.
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Figure I.1: Dierentiation process of stem cells; image adapted from [6]
After 2- 3 week in culture it occurs the loss of their tissue-specic prop-
erties until they return to be pluripotent in a state that is like hESC. Then
they can be dierentiated into several phenotypes. This approach opens a
wide range of promising new medical therapies (FigureI.2)
• Regenerative medicine;
• Creation of pathology-specic cell models that can be used for research
and development of new drugs;
• Production of patient-specic healthy somatic cells;
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Figure I.2: Application of hiPSC; image adapted from [7]
I.3 Stem cell dierentiation into cardiomyocytes
There are several methods that can dierentiate human pluripotent stem cell
into cardiomyocytes [8]. One of them, called hanging drop method, consist
in inducing hESCs and hiPSCs to the spontaneous dierentiation into CMs
through the formation of a particular 3 dimensional aggregates of pluripotent
cells, called Embryoid Bodies. These are obtained by dissociating pluripotent
stem cells into small clusters and then removing them from the environment
supporting their undierentiated state. After few days from the formation of
EBs, they are plated on cultured plates. Then, in about one day, spontaneous
beating areas on the culture can be observed, establishing the dierentiation
into the cardiomyocytes.
Another method consists in adding to the stem cell culturing mouse
endodermal-like cells. These one will secrete a dierentiation inducing factor
which is still under studies because it is not fully understood yet. One more
method is based on using grow factors which induce the dierentiation into
5
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mesodermal-like and endodermal-like cells, since the rst is the responsible
of the formation of cardiac tissue and the latter is responsible of the signal
generating tissue[10].
Unfortunately, all these methods have a very low eciency: cultures with
mouse endodermal-like cells have an eciency between 2.9%-9.4% and cul-
tures with EBs methods have eciency between 1.6%-12.5%. So, better
dierentiation methods should be found to let the hESCs and hiPSCs be
usable tools for future cell therapies and pharmacological studies.
Furthermore, as stated before, with hiPSCs it is possible to replicate not
only cells from healthy donors, but also from subjects carrying particular
genetic mutations, giving the opportunity to make accurate and patient-
specic in vitro studies of that specic pathology. Currently, many studies are
focused on the Long QT syndrome(LQTS). As the name suggests, subjects
aected by this pathology are characterized by a long QT interval on the
ECG due to an abnormal prolongation of the ventricular repolarization. This
disease leads to an abnormal heartbeat and may cause syncope, faintness and
ventricular brillation[11]. Dierent gene mutations cause LQTS and some
of them are under investigation by using hiPSCs culture from LQTS positive
patients:
• LQT1, aecting the KCNQ1 gene that encode for the repolarizing slow
delayed rectier current (IKs) channel, causing its loss-of-function;
• LQT2, mutating the KNCH2 gene that encode for the fast-delayed
rectier current (IKr) channel, causing its loss-of-function;
• LQT3, which mutates the SCN5A gene which encodes for the depolar-
izing sodium current (INa), causing its gain-of-function, and, in partic-
ular, an inward Na+ leakage during the repolarization of the membrane
potential;
• LQT8 (Timothy syndrome) in which CACNA1C gene encoding the L-
type Ca2+ current (ICaL) channel mutates, causing a delay in the closure
of the ICaL channels;
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I.4 The cardiac action potential
An ction potential(AP) consists in the rapid membrane potential depolarization-
repolarization sequence as a consequence of an external stimulus or sponta-
neously triggered.
The cardiac muscle is a highly organized structure and his functional
unit, responsible of the contraction, is the cardiomyocyte (CM). There is
also a little part of them, called peacemakers cells, able to the spontaneously
generate an AP, thus giving the heart a self-contracting property.
As shown in[12], the excitation-contraction (EC) coupling in the myocar-
dial tissue is started by the AP generated from the peacemaker cells. When
the AP reaches a contractile cell causing its membrane depolarization, due
to the ion current transfer, the Ca2+ intracellular concentration increases.
This Ca2+ increase starts, with the activation of the myolaments, the cross-
bridge mechanism resulting in the cell shortening. All the CMs should be
very coordinated during the heart beating in order to have an ecient pump-
ing action and a proper body perfusion. The heart electric activity can be
recorder through ECG. The ECG track represent the sum of the whole APs
generated by the CMs, since the AP assumes dierent waveform according
to the location in the heart where it is recorded (FigureI.3).
The most representative shape is the ventricular one and this will be
used to explain the mechanism behind the cardiac AP. The AP waveform
can be divided in 5 phases (FigureI.4) corresponding to dierent activation
and inactivation of ionic currents and pumps:
• phase 4: the membrane potential is kept stable at about -90 mV by
dierent mechanism:
 The inward rectier K+ current IK1 that causes a ux of K
+ ions,
whose equilibrium potential primary denes the CM membrane
potential;
 The ATP-based Na+/K+ pump (INaK) which transports 3 Na
+
ions toward the extracellular space and brings 2 K+ ions into the
intracellular compartment, thus generating a outward current;
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Figure I.3: AP genesis from dierent cardiac regions.; image adapted from
[13]
 The bidirectional Na+/Ca2+ exchanger (INaCa) which allows the
exchange of 1 Ca2+ ion for 3 Na+ ions dependently to the concen-
tration gradient; together with the Ca2+ ATP-ase (IpCa) it balance
the intracellular Ca2+ concentration and consequently keeps the
resting potential;
• Phase 0 : when the CM membrane potential reaches a voltage thresh-
old at about -60 mV it increases shortly to 40-50 mV resulting in an
upstroke. This potential steep slope is due to Na+ current (INa), a
fast Na+ inux following the electrochemical Na+ gradient along the
membrane;
• Phase 1 : INa rapidly inactivate while a transitory outward K+ cur-
rent (Ito) activates that causes a transient K+ eux along the elec-
trochemical gradient; in the ventricular cells Ito induces the typically
spike-and-dome shape;
• Phase 2: the ICaL reaches its peak and sustains the AP plateau. This
current activates previously during the upstroke but reaches its maxi-
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mum during the plateau since it has a slower dynamic than INa;
• Phase 3: represents the repolarization of the membrane potential and
it is induced by the rapid delayed rectier K+ current (IKr) and the
slow delayed rectier K+ current (IKs);
Figure I.4: Ventricular AP phases; image adapted from [13]
Since this thesis deals with the calcium handling during the AP It is worth
to spend more words about Ca2+ physiological role during the contraction
mechanism and how can an AP trigger the CM contraction. There are some
elements involved in this phenomenon: The L-type Ca2+ channels, the T-
tubules, the sarcoplasmic reticulum (SR) and the sarcomeres. SR represents
a structure inside the cytosol where the Ca2+ is stored at high concentration
and it has two main channels to communicate with the cytosol: Serca-2 pump
(Ca2+ intake) and the Ca2+ ryanodine-sensitive release channels. Its role
it to regulate the cytosolic Ca2+ concentration. T-Tubules are specialized
structure which let the L-type Ca2+ channels and the SR Ca2+ discharge
system to be close to each other. The sarcomere represents the cell contractile
unit, composed by actin and myosin laments, which will shorten in presence
of Ca2+ (cross-bridge mechanism).
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Figure I.5: hiPSC-CM spontaneous APs from dierent cell classes.; image
adapted from [16]
ICaL channels open when the AP res, but the small amount of Ca
2+
isn't enough to trigger the crossbridge mechanism. But this small amount
of Ca2+ is sucient to trigger Ca2+ release from SR, in a positive feedback
process called Calcium Induced Calcium Released (CICR), which increases
the intracellular Ca2+ concentration by about 100-fold, allowing the cellular
contraction [14]
In order to keep the intracellular Ca2+ concentration at adequate levels,
ATP-dependent SERCA pump moves Ca2+ from cytosol back to the SR and
INaCa, together with IpCa, extrudes Ca
2+ towards the extracellular space. Car-
diomyocytes derived from hESCs (hESC-CMs) or hiPSCs (hiPSC-CMs) be-
have like not fully mature cardiomyocytes, thus showing partly dierent AP
shapes compared to adult myocytes. The main dierences concern the spon-
taneous APs, a feature present in hESC-CMs and hiPSC-CMs but only in
adult nodal cells, and some morphological features such as the more positive
Maximum Diastolic Potential(MDP), that is the most negative transmem-
brane potential, or the smaller Maximum Upstroke Velocity (
dV
dtmax
,that is
the maximum value of the slope during the upstroke[15][16]. Another as-
pect regards the more heterogeneous AP shapes shown by hESC-CMs and
hiPSC-CMs: they can still be classied among ventricular-atrial and nodal-
like according to their similarity to the respective adult phenotype, but they
show higher variability of their electrophysiological properties (FigureI.5).
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I.5 Action Potential modelling: the Hodgkin-
Huxley paradigm
Since during this thesis work the Hodgkin-Huxley (HH) modelling paradigm
was mainly used, a short summary of its fundamental equations is here pro-
vided. The HH model is mathematical model describing the generation and
propagation of the neuronal AP and it is one of the most successful mathe-
matical models of a complex biological process that has ever been formulated
[18][17]. Despite the original HH model was formulated for one specic cel-
lular species, the HH modelling paradigm is used also to describe adequately
a generic AP and, in our case, the cardiac AP.
The fundamental equation used to obtain the AP expression as a function
of time, i.e. the evolution in time of the transmembrane potential Vm(t), is:
dVm
dt
=
Iion
Cm
(I.1)
where Iion is the sum of all the ionic currents and Cm is the membrane ca-
pacitance.
The mathematical equation used to describe the generic ionic current
owing through the membrane is:
I = xa ∗ yb ∗Gmax ∗ (Vm − Er) (I.2)
where Gmaxis the maximum channel conductance, Er is the resting potential
for a specic ionic species and is computed as Nerst potential as follows:
Er =
RT
zF
∗ ln [ion]o
[ion]i
(I.3)
x(Vm,t) and y(Vm, t) are the gating variables, respectively the activation
and inactivation gating variable. The meaning of these can be explained
considering that the ionic current amplitude is proportional to the open gates
in that specic channel. A generic gating variable describe the fraction of the
open (and the closed) gates, so it will be always inside the range [0, 1]. The
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transition from open to closed and vice versa is described by this formulation:
dx
dt
= αx ∗ (1− x)− βx ∗ x (I.4)
If the values of αx and βx depend on Vm, then the state of the gating vari-
able is voltage dependent. This means that activation gates will have a
value proportionally dependent to the membrane depolarization while the
inactivation gates will have a value inversely proportional to the membrane
depolarization.
Imposing:
αx =
xinf
τx
(I.5)
and
βx =
(1− xinf)
τx
(I.6)
Equation I.4 can be reformuled as:
dx
dt
=
xinf − x
τx
(I.7)
where the stady state
xinf =
αx
αx ± βx
(I.8)
represents the value at which x tends at certain membrane voltage and it is
experimentally obtained by tting data using the following sigmoid function:
xinf =
1
1 + exp
Vm−Vh
K
(I.9)
In this new representation of xinf , Vh is the voltage of half activation and
K is the gradient of activation. The time constant:
τx =
1
αx + βx
(I.10)
measures the velocity of the gating variable x to reach its steady state.
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II.1 The computational model of hiPSC
During the thesis work the hiPSC-CM model from Paci et al.[19]was used It
reproduces the spontaneous AP beating of atrial and ventricular-like hiPSC-
CM, but for this work only the ventricular-like was considered.
A general overview is given in FigureII.1, which highlights the cell com-
partment, ion currents and pumps. Since the model is based on the HH
formalism, the membrane potential is formulated as:
C
dV
dt
=− (INa + ICaL + If + IK1 + IKr + IKs + Ito + INaCa
+ INaK + IpCa + IbNa + IbCa + INaL − Istim).
(II.1)
where C is the membrane capacitance and V the membrane potential. Istim is
the stimulus current, which was used to replicate specic experimental drug
test protocols in the original publication.
The intracellular K+ concentration is kept constant, due to a legit ap-
proximation because the amount of K+ transferred between intracellular and
extracellular compartments is very low compared to K+ intracellular concen-
tration. The others ion concentrations are described as follow:
13
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Figure II.1: : Schematic diagram of the model; image adapted from [19]
dNai
dt
=
INa + IbNa + 3INaK + 3INaCa
FVc
(II.2)
dCaii,total
dt
= Ileak − Iup + Irel −
ICaL + IbCa + IpCa − 2INaCa
FVc
(II.3)
dCaSR,total
dt
=
Vc
VSR
(Iup − Irel − Ileak) (II.4)
where F represents the Faraday constant, Vc and VSR are the cytosolic and
sarcoplasmic volume respectively, Cai,total and CaSR,total are the intracellular
and sarcoplasmic concentration respectively of Ca2+, either free buered.
Referring to FigureII.1, the model present:
• Ion currents: L-type Ca2+ current ICaL, rapid delayed rectier K+ cur-
rent IKr, slow delayed rectier K
+ current IKs, outward transient K
+
current Ito, inward rectier K
+ current Ik1, funny current If, Na
+ cur-
rent INa, late Na
+ current INaL, background Ca
2+ current IbCa, back-
ground Na+ current IbNa;
• Ion exchangers: Na+/Ca2+ exchanger INaCa;
14
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• Pumps: Na++/K+ pump INaK and sarcolemmal Ca2+ pump IpCa;
• Fluxes from/to the SR: Ca2+ SR release Irel, Serca ATP-ase pump and
leakage ux Ileak;
INa, ICaL, If, Ito, IK1, IKr and IKs were tted on the experimental data from
Ma et al.[16]. Where no experimental data were available, the ion currents
were adapted referring to a previous hESC-CM model[20].
AP shapes are analytically compared using morphologic biomarkers, the
AP features. In this case the following were considered:
• Cycle Length;
• Rate of spontaneous beating expressed in bpm;
• MDP: maximum diastolic potential;
• Peak: maximum voltage reached by the AP;
• APA: action potential amplitude, calculated from MDP to APA;
• Vmax: is the maximum value of the slope during the AP upstroke;
• APD10, APD30 and APD90: action potential duration computed re-
spectively at 10%, 30% and 90% of the repolarization;
• RappAPD: is a shape factor calculated as follow APD30−APD40APD70−APD80 ;
In TableII.1 a AP features comparison with experimental measurement
can be found.
15
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Table II.1: Comparision between experimental and simulated ventricular
AP. Experimental data are presented as: Mean± SEM
AP Features Unit EXP SIM
Cycle Length s 1.7± 0.1 1.6
Rate of sponta-
neous beating
bpm 35.3± 2.2 37.4
MDP mV −75.6± 1.2 −76.7
Peak mV 28.3± 1.0 28.1
APA mV 104± 1.1 104.8
dV
dt
max
V
s
27.8± 4.8 24.4
APD10 ms 74.1± 4.8 63.4
APD30 ms 180± 10.7 238.9
APD90 ms 414.7± 21.8 417.5
RappAPD - 2.5± 0.2 3.17
16
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II.2 Ca2+ dynamic and limitations of the model
The Ca2+ have a key role during the EC coupling, since it is needed to
activate the crossbridge mechanism. As explained in Chapter 1, in order
to achieve a cell contraction, a relatively huge amount of Ca2+ is needed in
the intracellular compartment. During phase 1 of the ventricular AP, ICaL
activates, carrying Ca2+ inside the cytosol, but it is not enough to trigger the
contraction. However, it is enough to activate the CICR, mechanism. The SR
has Ca2+ sensitive receptors (ryanodine sensitive, RyR-sensitive, receptors)
sensing the Ca2+ concentration in the cytosolwhich allow the Ca2+ release
from the SR when they sense the intracellular Ca2+ increment due to ICaL.
This establishes a positive feedback mechanism since the more Ca2+ is carried
inside cytosol from ICaL and Irel, more Irel ows, causing a Ca
2+ concentration
increase, which allows the cell contraction.
The model replicates this process well but in a simplied way. Although
the Irel activation physiologically relies on the Ca
2+ binding to RyR-sensitive
receptors, in the model formulation, it relies directly on the ICaL voltage-
dependent activation variable. So Irel is not directly triggered by intracellular
Ca2+ increase. This approximation was meant to simplify the Ca2+ handling
description, due to the lack of solid experimental data on Ca2+ handling in
hiPSC-CM at the time the original Paci2013 model was developed. Despite
it can reproduce Ca2+ transient, a new Irel formulation is needed to obtain a
more physiological behavior of the model.
II.3 Novel Irel formulation
After a literature review, an accurate formulation of Irel was found, from a
published human atrial CM model by Koivumäki et al[21]. Based on the HH
formulation, the Koivumaki model presents a novel formulation of the SR
compartment and Ca2+ release current. The SR compartment is divded into
four parts and each of them is provided with an uptake unit (Iip) and a re-
lease unit (Irel). This spatial discretization is meant to be a well-functioning
approximation of the SR volume, since the model is integrated only along
17
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Figure II.2: role of adptation gate; gure adapted from[21]
the time dimension, allowing a realistic representation of Ca2+ transients.
Despite this, our intention was not to replicate the whole structure of the
Koivumäki model SR (since it could be not physiologically acceptable for
hiPSC-CMs, due to their underdeveloped SR, dierent from atrial cardiomy-
ocyte SR), but to nd a suitable Irel formulation which does not depend on
the ICaL voltage dependent activation variable. Therefore, we only used the
Koivumäki Irel formulation.
This novel Irel formulation respect the classical HH approach and it is
described by three Ca2+ concentration dependent gating variable: adaptation
gate, open gate, closed gate. The role of the adaptation gate can be explained
as follow: in FigureII.2 it is showed the probabilities of the open and closed
gates dependent of Irel concentration for two dierent state of adaptation
So, the adaptation gate can shift the point of dynamic equilibrium ac-
cording to the Ca2+ concentration in the cytosol [Ca2+]i In gure 2.3 two
illustrative examples are shown: on the left column the adaptation gate is
functioning, so, in presence of an reduced Ca2+ extrusion towards the extra-
cellular environment, i.e. a change of the working condition, the system is
able to compensate and prevent Irel to shut down (this can be observed by
the Ca2+ transient peaks, since Irel carries Ca2+ ions inside the intracellular
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Figure II.3: : Dierences betweed model with non-inhibited (left column)
and inhibited (right column) adaptation gate in the Koivumäki model. The
reduced Ca2+ extrusion (0.33-fold) was implemented by reducing by 67%
INaCa, IpCa and Iup; image adapted from [21]
compartment). On the other hand, in the right column, this compensation
does not happen, because the adaptation gate is inhibited.
Compared to the Paci2013 hiPSC-CM model Irel formulation, the Koivu-
maki one allowed us to disconnect Irel from ICaL, at the price of a slightly
higher computational cost, due to the introduction of two additional dif-
ferentai lequations for the adaptation and the open gate (the close gate was
already included in the original Paci2013 hiPSC-CM model). However, since
we need to use a formulation taken from an adult CM model in a hiPSC-CM
model, further steps should be followed to obtain a model properly simulat-
ing APs and Ca2+ transients of hiPSC-CMs. Substantial dierences, such as
cell volume, compartments volume, and ionic concentrations, requires a ne
tuning of the mathematical Irel formulation parameters.
Furthermore, the availability of experimental data of Ca2+ transient give
the opportunity to t Irel parameters in a more accurate form. This procedure
can be achieved in dierent ways, such as a manual parameter tuning, but we
chose to use an automatic procedure based on an optimization framework,
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that will be discussed in the next section of this chapter.
II.4 Experimental data of Ca2+ transients
The Ca2+ experimental data used to tune the Irel parameters were obtained
by measures on actual hiPSC-CMs, performed at BioMediTech
(www.biomeditech.), a joint institute of Biomedical Sciences and Engineer-
ing of the Tampere University of Technology and the University of Tampere
(Finland). Such data consist in a set of Ca2+ transient features concern-
ing magnitude and duration values. Measurements were made with calcium
imaging. This kind of measurement is widely used to show the Ca2+ status
of a cell through some Ca2+ sensitive uorescent dyes. Those molecules are
able to change their uorescence properties after binding selectively to Ca2+
ions. The variation of this uorescent signal, acquired with a CCD camera,
can describe the amount of Ca2+ inside a cell. In particular, to quantify the
Ca2+, is necessary to perform a system calibration since the Ca2+ transient
amplitude is relative to the basal uorescence of the dyes, i.e. the uorescence
observed when no Ca2+ transient occurs.
Therefore, it is not possible knowing the absolute value of features con-
cerning magnitude (e.g. amplitude of the transient expressed as mM), unless
performing the calibration of the dye. Unfortunately, such calibration is usu-
ally not done by the biologists who recorded Ca2+ data. For this reason, only
time-domain features are considered, as listed below:
• Time to peak: time needed to reach maximum Ca2+ concentration
value;
• Maximum rise slope: maximum value of the slope reached by the
Ca2+ transient;
• Rise time 10% to 90%: time that occurs to rise from the 10% to the
90% of transient amplitude;
• Rise slope 10% to 90%: average slope from 10% to the 90% of
transient amplitude;
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Figure II.4: Time domain biomarker of a Ca2+ transient. The Maximum
Rise Slope is maximum value of the slope between the two green dots. Rise
time from 10 to 90% and Decay slope from 90 to 10% are calculated as an
average of the slope between the red and yellow dots respectively.
• Decay time 90% to10%: time that occurs to decay from the 90% to
the 10% of transient amplitude;
• Decay slope 90% to 10%: average slope from 90% to the 10% of
transient amplitude;
• Event frequency: transient frequency;
In FigureII.4 is illustrated how are the biomarkers calculated from a single
Ca2+ transient.
II.5 Cell Classication
The in vitro measurements were performed on a 13 hiPSC-CM cells, several
times for each cell (from 2 to 5 times) and are presented asMean±SD. Since
no information about the cell phenotype (e.g. atrial-like or ventricular-like)
was given and the model we replace Irel is the ventricular-like version of the
Paci2013 hiPSC-CM model, a classication of experimental data is needed.
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Due to the lack of any prior information about the cell phenotypes, the most
suitable choice is an unsupervised classier.
K-means algorithm is used in order to perform a clusterization into two
class, atrial and ventricular-like. Three Ca2+ transient features are used as
discriminating factors for the algorithm: Decay slope 90% to 10%, Decay tau,
Event frequency. The reason behind this choice can be explained considering
some dierences between atrial and ventricular spontaneous activities. In
[22][16] it is shown that atrial-like cells have a more rapid spontaneous beat-
ing activity, resulting in a higher basal beating frequency. Ca2+ transient
follow this faster spontaneous activity, so a discrimination based on beating
frequency and decay slope results to be the most accurate one. In addition
to the Decay slope 90% to 10% and Event frequency, described in the previ-
ous section, for clustering we used also the Decay tau feature, i.e. the time
constant of the exponential curve used to t the Ca2+ transient decay.
II.6 The Optimization framework
The optimization procedure consists in using a framework able to tune au-
tomatically the model parameters. The main idea come from a previous
published work [23] used for the same purpose but for a dierent cell model.
Shortly, the framework calculates a cost function and tries to minimize it,
giving as result an optimal parameter set. The framework is implemented
in Matlab and it is based on the fminsearch function, a powerful tool for
function optimization.
As shown in FigureII.5, the workow of the algorithm consists in an itera-
tive process that starts from an initial parameter set. The choice of the target
parameters is crucial for the following reasons. A too large set of parameters
is dicult or impossible to optimize, so it is important to choose the most
relevant parameters. Moreover, since experiment-based parameter tuning
was already done for several ions current formulations during the Paci2013
hiPSC-CM model development[19], only parameters of the few currents for
which experimental data were not available at the time of the development
of the Paci2013 model should be chosen, in addition to the Irel formulation
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Figure II.5: 5 Working principle of the optimization framework.
ones.
After these considerations, 11 parameters were chosen as the most appro-
priate ones, as listed below:
• Vmax.up: maximum conductance of the SERCA pump, also called Iup;
• Kup: parameter that regulate the equilibrium of the SERCA pump;
• KNaCa: maximum conductance of INaCa;
• alphaNaCa: parameter that regulates the equilibrium of INaCa;
• PNak maximum conductance of INaKl;
• Vleak : maximum conductance of Ileak;
• Girel maximum conductance of Irel;
• RyRa1 parameter of the steady-state variable in the Irel formulation;
• RyRa2 parameter of the steady-state variable in the Irel formulation;
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• RyRahalf half-activation concentration of the Irel adaptation gate;
• RyRohalf half-activation concentration of the Irel open gate;
• RyRchalf half-activation concentration of the Irel closed gate;
The next step that the framework requires is to dene a cost function.
This function is based on this formula:
C =
∑
i
∆i
σi;exp
∗ wi (II.5)
Where C is the cost, σi;exp is the SD of the i
th experimental feature, wi
is the weight assigned to the ith feature and ∆i is the dierence between the
experimental and simulated ith feature. ∆i can assume:
• 0, if the simulated feature is within the experimental rangeMean±SD;
• |Featsim−σi;exp|,where Featsim is the value of the feature simulated., if
Featsim is outside the experimental range Mean± SD;
This function will give an output cost proportional to how much the sim-
ulated data are close to the experimental ones. So the overall cost is given by
the sum of each single feature contribution properly weighted. This contri-
bution will increase in a linear way if the feature is outside the experimental
Mean ± SD, otherwise the cost is null. The set of target features used for
the optimization process consists in two parts:
• the AP features from[16], which were used to tune the original version
of the Paci2013 hiPSC-CM model. This feature set is necessary to keep
the in silico AP shape consistent with the experimental hiPSC-CMAPs.
• the Ca2+ features computed on the in vitro Ca2+ transients, explained
in section 2.4.
Furthermore, in order to calculate these features from simulated traces
of APs and Ca2+ transients a novel features extraction function was created
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ad hoc and it is formed by two parts. The rst part is able to extract a time
window relative to the last 5 APs from the whole model simulationc, since
the features must be extracted when the system reaches the steady state. On
the other hand, the second part calculate the features for each of these 5 APs
( and also 5 Ca2+ transients, since for each AP correspond a Ca2+ transient)
and average them.
II.7 Model Validation through currents blocker
simulations
During the experimental recording accomplished by Ma et al on hiPSC-CM,
current blockers measurements were done. Those measurements consist in
using drugs that are able to selectively block an ion channel, thus resulting
in an AP shape variation. Depending on which current blocker is used, the
AP shape changes in dierent ways, since each ion activates in dierent AP
phases, as shown in Chapter 1. Since the goal of this thesis is to develop
a model which accurately reproduces the electrophysiological behaviour of
hiPSC-CM, simulations of the eects of current blockers provide a useful
form of validation on the model.
The simulated current blockers presented here are tetrodotoxin (TTX),
nifedipine (Nifed) and E4031 that are selective current blocker for INa, ICaL
and IKr respectively. To simulate these blockers, the maximum conductance
of the target current is reduced according to the dose-response curves, which
are the experimental quantication of the blocking eect on the current tar-
geted by the blocker. We simulated the same experimental protocol used
in Ma et al: pacing rate xed at 1 Hz, depolarizing pulses of 5 ms with an
amplitude of 550 pA for Nifed and E4031 and 750 pA for TTX.
25

CHAPTER III
Results
All the results obtained during this thesis work will be illustrated in this
chapter. The experimental data gathering and classication will be shown.
Then the optimization framework results will be presented as well as the
electrophysiological behaviour of the model with the new Irel formulation
implemented and tuned.
III.1 Experimental Calcium data classication
The experimental measurements were performed on a set of hiPSC-CM wild
type using calcium imaging technique. The Ca2++ traces were acquired with
a variable frame rate from 9 Hz to 26 Hz and then analysed with ClampFit
software. Since no information about the cell culture lineage is available, it
is not possible to discriminate them into atrial or ventricular-like. Therefore
we used an unsupervised classication tool in order to attempt to discrimi-
nate between atrial and ventricular-like phenotypes and to have a better and
accurate set of experimental measurement for the next steps of this thesis.
The data come from a set of 13 cells which the features are extracted from.
The measurements are performed N times on each cell and then the results
are presented asMean ± SD. In Table 3.1 it is reported an example data
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Table III.1: Example of experimental data sheet. The features are:
TP=time to peak ; dCai
dt
max=maximum rise slope ; RT1090= rise time from
10 to 90% ; RS1090= rise slope from 10 to 90%; DT1090= decay time from
90 to 10%; DS9010= decay slope from 90 to 10% ; FREQ= event frequency.
N is the number of single cell measurement repetition
Feature Unit Mean SD N
TP ms 274.286 56.25 14
dCai
dt
max Mol
s
2.22 0.51 14
RT1090 ms 165.49 30.48 13
RS1090 Mol
s
0.93 0.62 13
DT9010 ms 238.542 31.75 14
DS9010 Mol
s
-0.673 0.235 14
Frequency Hz 1.406 0.180 13
sheet of a single cell.
After the experimental data collection, a Matlab script was set up to per-
form the classication with the K-Means function. The algorithm needs the
target features to classify our set of cells and, as we described in the previous
chapter we used the Decay slope 90% to 10%, Decay tau and Event frequency,
since time-domain features represent, in our situation, the best discriminat-
ing factors. Furthermore K-means requires the features to be normalized
rst and, after this operation, we started the classication procedure. This
procedure is mandatory since our variables have incomparable units (e.g De-
cay tau in ms and Event frequency in Hz) and they need a standardization
to be equally classied. The results of the algorithm are reported below
(FigureIII.1,FigureIII.2). For a clear and understandable presentation of the
results, is was chosen to show only two features for each gure, although the
features-space is 3 dimensional (Decay slope 90% to 10%, Decay tau, Event
frequency).
K-means divided the 13 cells into two classes that we associated with the
phenotypes ventricular-like (9 cells) and atrial-like (4 cells). After classi-
cation, we can represent them with their original measurement units (Fig-
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Figure III.1: Distribution of normalized features into the two-dimensional
features space. In green are also reported the centroids of the clusters
ureIII.2).
Looking at the gures with original values, the cells classied as atrial-like
present generally a higher beating frequencies, faster decay constants as well
as shorter Decay Time. On the contrary, the cells classied as ventricular-
like have slower beahviour: lower beating frequencies, slower decay constants
and longer Decay time. This results are coherent with the experimental
ndings([16][22]) and considering that no a priori information was given to
classify the data set so we can hypothesize this result as reliable.
After classication, mean and standard deviation were extracted from the
9 ventricular-like cells to use them in the optimization framework. Results
are presented in TableIII.2.
29
CHAPTER III. RESULTS
100 200 300 400 500 600 700 800 900 1000
Decay tau (ms)
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
F
 (
H
z
)
ventricular like
arial like
Legend
150 200 250 300 350 400 450 500 550 600
DecayTime90to10 (ms)
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
F
 (
H
z
)
100 200 300 400 500 600 700 800 900 1000
Decay tau (ms)
100
200
300
400
500
600
D
e
c
a
y
T
im
e
9
0
to
1
0
 (
m
s
)
Features with original measurement units
Figure III.2: Distribution of normalized features into the two-dimensional
features space.
Table III.2: : Mean and SD of the biomarkers recorded on the 9 cells
classied as ventricular-like.
Feature Unit Mean SD
TP ms 399 105.4339
dCai
dt
max
Mol
s
3.5583 1.6786
RT1090 ms 28 55.83
RS1090
Mol
s
1.1221 1.2413
DT9010 ms 481 64.0934
DS9010
Mol
s
-0.8119 0.5706
Frequency Hz 0.5277 0.1151
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Table III.3: Initial parameter set used in the optimization framework.
Parameter name Value
Vmax,up 0.56064
Kup 0.00025
KNaCa 5978
alphaNaCa 2.8571
PNaK 2.2958
Vleak 0.00044
Grel 64
RyRa1 0.505
RyRa2 0.427
RyRahalf 0.29
RyRohalf 0.22
RyRchalf 0.02
III.2 Optimization framework results
At this point, the result from the experimental data classication can be
used in the optimization framework cost function to compare also the Ca2+
features simulated by the model.
As explained in the previous chapter, the cost function uses both AP and
Ca2+ features to compute a cost. In addition to the Ca2+ features, we used
the same experimental AP features used to develop the hiPSC-CM Paci 2013
model from Ma et al [16].
Referring to FigureII.5 in the previous chapter, the framework needs an
initial parameter set to start the optimization procedure. Since the aim is not
to change drastically the model behaviour, but only to tune formulation lim-
ited set of parameters, it was chosen to start the optimization procedure with
the same parameters of the Paci2013 model. On the other hand, concerning
the new Irel formulation parameters, it was used the same parameters set of
the original published paper III.3.
The overall cost is calculated as the sum of all the single feature cost.
This value is proportional to how much the features is outside the exper-
imental range Mean ± SD. Despite the Ca2+ features were already cal-
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culated as Ca2+, AP features from Ma et al.[16] are presented as Mean ±
SEM(Standard error of the Mean). Since it was chosen to use the SD for the
cost function the SEM needs to be converted. The formula below expresses
the relationship between SEM and SD:
SD =
SEM√
N
Where N is the number of the observations(34).
Furthermore, each single feature contribution to the overall cost is weighted
by a scalar factor that allow to control and decide which features is worth to
be more considered or not. In TableIII.4 a summary of the features used in
the rst step of the optimization procedure is reported: the initial value of
the cost function is 9.78.
Table III.4: Summary of the biomarker used to initialize the cost function.
Feature Unit Mean SD Weight
APA mV 104 6.2225 1
MDP mV -75.6 6,7882 2
Cyclelength ms 1700 565.6854 2
dV
dt
max V
s
27.8 27.1529 1
APD10 ms 74.1 27.1529 1
APD30 ms 180 60.5283 1
APD10 ms 414.7 123.319 1
RAPPapd - 2.5 1.1313 1
TP ms 399 105.4339 0.2
dCai
dt
max
Mol
s
3.5583 1.6786 0.2
RT1090 ms 28 55.83 0.2
RS1090
Mol
s
1.1221 1.2413 0.2
DT9010 ms 481 64.0934 0.2
DS9010
Mol
s
-0.8119 0.5706 0.2
Frequency Hz 0.5277 0.1151 0.2
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Table III.5: : Optimized parameter set. It is also shown the starting
parameter set and the percent variation.
Parameter
name
Optimized Original Variation
Vmax,up 0.5785 0.56064 +3%
Kup 0.00027 0.00025 +7%
KNaCa 4868 5978 −22%
alphaNaCa 2.8095 2.8571 −1%
PNaK 2.4819 2.2958 +7%
Vleak 0.0004661 0.00044 +5%
Grel 64.805 64 +2%
RyRa1 0.4809 0.505 −2%
RyRa2 0.4541 0.427 +6%
RyRahalf 0.3001 0.29 +4%
RyRohalf 0.2154 0.22 −2%
RyRchalf 0.0204 0.02 +2%
Finally, the optimization was started. Due to the high computational
cost, the optimization procedure last for several hours and, at the end,
reached a result with a cost of 0.9. The optimal parameter set found by
the framework is reported in TableIII.5.
The previous table allows to see the changes between the initial and the
optimized parameter set. The variation goes from a 22% of the starting
value in case of KNaCa to the 1% of alphaNaCa. In the next section it will be
shown how the optimized parameter set aect the model electrophysiological
behaviour.
III.3 New hiPSC-CM ventricular-like model
Finally, we can present the hiPSC-CM ventricular like model with the opti-
mized parameter set.
The simulated AP traces and the major ionic currents are shown in Fig-
ureIII.3 during spontaneous electrical activity. The gures are obtained after
800 seconds of simulation to let the model reach the steady state. Further-
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Figure III.3: : spontaneous Ap, ionic currents and ionic concentrations at
model steady state. The measurement units are expressed in: Volts for the
AP; Ampere/Farad for the ionic currents; millimolar for the ionic concentra-
tions.
more, in Tab 3.6 there is the comparison between the simulated biomarkers
and the experimental biomarkers computed by Ma et al. for the APs and at
Biomeditech for the Ca2+ transients.
The table shows that the model is able to well reproduce the experi-
mental biomarkers. All the AP features, except the APD30, are within the
range Mean±SD. Moreover, the Ca2+ features dCai
dt
max, RS1090, DS9010
are within the experimental intervals as well. Referring to TableII.1, is also
useful to make a comparison between the new and the original model: the
APD30 is not reproduced by both, but now, with the optimized parame-
ters, the new hiPSC-CM model can successfully reproduce the APD10 and
RAPPAPD.
In order to have a better overview about the new changes introduced in
the Paci2013 model, a comparison between the AP and intracellular Ca2+
traces produced by the old and new version of the model are presented be-
low. In g FigureIII.4 it can be observed that the new model AP trace has
a slightly higher maximum peak voltage (+11%) but the same maximum
diastolic potential . On the other hand, Ca2+ transient in g 3.7 shows that
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Table III.6: Comparison between experimental biomarkers and those simu-
lated by the hiPSC-CM ventricular-like model with the optimized parameter
set values.Data are presented as Mean± SD
Feature Unit EXP SIM
APA mV 104±6.2225 107.9639
MDP mV -75.6±6,7882 -76.6234
Cyclelength ms 1700±565.6854 1539
dV
dt
max
V
s
27.8±27.1529 24.7196
APD10 ms 74.1±27.1529 77.6250
APD30 ms 180±60.5283 250.125
APD10 ms 414.7±123.319 400.25
RAPPapd - 2.5±1.1313 2.6583
TP ms 399±105.4339 149
dCai
dt
max
Mol
s
3.5583±1.6786 3.1790
RT1090 ms 28±55.83 78
RS1090
Mol
s
1.1221±1.2413 2.3027
DT9010 ms 481±64.0934 335.25
DS9010
Mol
s
-0.8119±0.5706 -0.5392
Frequency Hz 0.5277±0.1151 0.6497
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Figure III.4: Spontaneous AP comparison after 800 s simulation.
the systolic Ca2+ is lower in the new model (-13%) while the diastolic Ca2+
is not signicantly aected by the changes in the model.
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Figure III.5: Spontaneous Ca2+ transient comparison after 800 s simula-
tion.
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Figure III.6: INa blocker simulation
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Figure III.7: ICaL blocker simulation
III.4 Selective current blockers simulation
The TTX simulation consist in reproducing the eect of 3 ,10 ,30 µM of
TTX, that reduces the maximum conductance of INa (GNa) by 18%, 6%, 2%
respectively (FigureIII.6) The eect on are evaluated with a simulation of
3,10,30,100 nM of Nifed that reduces the ICaL maximum conductance (GCaL)
by 93%,79%,56%,28% respectively (FigureIII.7). Finally, a simulation of 30
and 100 nM of E4031 is performed by reducing the maximum IKr conductance
by 77% and 50% respectively ((FigureIII.8)). All these reduction percentages
were estimated from the dose-response curves reported in[19].
In TableIII.7 the quantitative eects of current blocker on APD90 and
dV/dt max are reported. In FigureIII.6 it can be observed the eect of INa
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Figure III.8: IKr blocker simulation
block. INa is the main responsible current for the AP upstroke so its inhibition
shifts in time the AP peak. Also, in case of 6% and 2% of GNa reduction,
INa is not enough to trigger the AP for all the external stimulation pulses.
In FigureIII.7, the eect of ICaL reduction can be observed in a AP short-
ening as ICaL has the role of sustaining the AP plateau.
In FigureIII.8 IKr block produces an AP lengthening since IKr is the re-
sponsible of the membrane repolarization. Qualitatively the simulated APs
are consistent with the experimental ndings in [16]. With the introduc-
tion of the new Irel formulation, the model is still able to well reproduce the
current blocker experiments.
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Table III.7: Quantication of current blocker eects on
dV
dt
max and APD90
AP Features Experiments Simulations
dV
dt
max
TTX 3µM 41.2±11% 18%GNa 23%
TTX 10µM 16.7±1.8% 6%GNa /
TTX 30µM 61.8±2% 2%GNa /
APD90
Nifed 3nM 89.4±1% 93%GCaL 96.53%
Nifed 10nM 78.4±4.4% 79%GCaL 85.9%
Nifed 30nM 74±2.3% 56%GCaL 65.7%
Nifed 100nM 58.2±5.4% 28%GCaL 43.8%
APD90
E4031 30nM 140.3±7.6% 77%GKr 120%
E4031 100nM 170.4±13.6% 50%GKr 157.9%
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Conclusions
The aim of this thesis was to improve the Ca2+ handling mechanisms, in par-
ticular the Ca2+ release from the SR, in the already published Paci model of
the AP of hiPSC-CMs[19]. Such model is the rst hiPSC-CM model available
in literature and it has been used for many applications, such as the compar-
ison of the eects of drugs on hiPSC-CMs and adult cardiomyocytes[24] or
the evaluation of the electrophysiological variability on the long QT 3 muta-
tion and drug eects in hiPSC-CMs[25]. However, the Paci model suered
from a very simplied description of the Ca2+ handling, which was inherited
from the TenTusscher 2004 model of adult ventricular cardiomyocyte [17].
Specically, the accompishments achieved during this thesis work consist
in:
• the adaptation of the optimization framework, published in [23], to
the hiPSC-CM modelling problem, which can be used also for further
improvements of the hiPSC-CM model;
• an improved and more realistic Irel formulation, which accurately re-
produces the biological mechanism of Irel activation;
• a new model parameter set chosen by the optimization framework by
means of AP literature data and Ca2+ transient traces experimentally
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recorded at BioMediTech;
• an unsupervised classier to process the experimental Ca2+ transient
data, in particular to infer their ventricular or atrial-like origin.
• a new version of the Paci hiPSC-CM model which exploits the new Irel
formulation, but still is able to reproduce all the experimental data it
was able to reproduce in its original formulation.
The introduction of the new Irel formulation, that has a cytosolic Ca2+
concentration-dependant activation gate, allows the Paci2013 to overcome
the limit imposed by the old Irel formulation, which was dependent on the
ICaL voltage-dependent activation gate.
The optimization procedure lead to another achievement: the model is
now able to reproduce two more AP features: APD10 and RAPPAPD. Consid-
ering the relevance of RAPPAPD inMa et al.[16], the result can be considered
a valuable achievement, since this feature is used to discriminate between
atrial-like and ventricular-like.
Moreover, this thesis work has provided, with the optimization frame-
work, a powerful and suitable tool to be used in model parameter tuning.
One of the major limitation encountered during this thesis work is rep-
resented by the high variability of hiPSC-CM. This can be attributed to
several reasons that can space from experimental environment dierences
in the hiPSC-CM culturing phase to substantial dierences among patients
from which hiPSC-CM are produced. Our optimization process is based on
dataset that came from two dierent culturing cells lines; we used the dataset
from Ma et al [16] to compute the cost for AP features and the dataset from
Biomeditech to compute the cost for the Ca2+ features. Since no information
about the Ca2+ traces was given in dataset from Ma et al and, conversely, no
information was given about the AP traces in the dataset from Biomeditech,
we are not able to detect and quantify if there are some substantial dierences
between the two datasets. Despite this, it can be observed (TableIII.4) that
the AP Interval and the Ca2+ Event Frequency, after the conversion in Hz
from bpm, present similar values of 0.5882 and 0.5277 respectively, but still
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there are no other evidences about the two-dataset similarity. We took into
account this uncertainty on experimental data by choosing dierent weights
in the cost function. Basically, we decided to assign a higher weight to AP
feature compared to Ca2+ features.
The high variability in hiPSC-CM put some limits in cardiac modelling
because it became dicult to reproduce with a single model formulation,
datasets that come from dierent cell lines. Since the Paci2013 was developed
according to a single data source (i.e. the dataset from Ma et al [16]) and, in
literature, Ca2+ dynamic in hiPSC-CM are still under study and is still not
well-known, we decided to assign higher value to AP features to prevent the
optimization framework from nding an inconsistent parameter set.
Another limitation could be represented by the lack of information about
phenotype of the cell used for Ca2+ transient measurement. In Ma et al [16]
the discriminating criterion used to classify cells between atrial-like and
ventricular-like was the RAPPAPD: cells with this ratio > 1.5 were classied
as ventricular-like. In our case, data provided by Biomeditech concerns only
Ca2+ features so we were not able to use the same criterion. Unfortunately,
the new hiPSC-CM model is not able to reproduce all the Ca2+ features. In
particular, dierences between the experimental and simulated values of TP,
RT1090 and DT9010 suggest that the high variability of hiPSC-CM should
be taken into account. Such variability could make very dicult conjugating
in the same in silico model in vitro data from two dierent sources (Ma et
al [16] and BioMediTech).
In the end, using an automatic procedure to tune the model parameter
brings clear advantages as well as some limitations. Compared to a manual
parameter tuning, the optimization framework oers the possibility to test
a wider range of parameter sets in a relatively short time, but there is the
possibility to nd a not fully physiologically consistent parameter set at the
end of the optimization process. The procedure is based on a function mini-
mization through fmisearch tool, so there is the risk to encounter a local cost
function minimum instead of a global minimumor if the minimization prob-
lem itself could not be solved in an analytic way. There should be always a
well-ponderate preliminary setting to allow the procedure giving a consistent
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result. This setting includes: the right choice of initial parameter set, the
optimum trade-o of the target parameters and the proper weight choice.
In conclusion, in this work we showed that a carefully used optimization
framework allowed to exploit new Ca2+ experimental data to improve the
Paci hiPSC-CM model. This opens also prospective for future works, i.e. to
further improve this new formulation of the Paci model by means of other
mechanisms, such as the inositol 1,4,5-trisphosphate-dependent Ca2+ release.
However, the reliability of cardiac modelling is strictly related to the avail-
ability of experimental data: therefore, another expectation is that in future
more in vitro studies will be conducted to allow a continuous improvement
of in silico hiPSC-CM models.
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